Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Vitrolife AB (publ): Interim report January-March 2022: Building on our strong growth momentum

Vitrolife
Download the release
First quarter
  • Sales of SEK 752 (379) million, corresponding to an increase of 98% in SEK whereof currency effect 13%, acquired growth 74% and organic growth 11%.
  • Consumables increased sales by 26% in SEK, Technologies by 4% in SEK, and Genetic Services contributed with sales of SEK 304 million.
  • Strong growth in all market regions: Americas 255%, EMEA 85%, Japan Pacific 21% and Asia 19% in local currencies.
  • Operating income before depreciation and amortisation (EBITDA) was SEK 228 (163) million, corresponding to a margin of 30.4% (43.0). EBITDA per share increased 13%.
  • Net income was SEK 82 (119) million, resulting in earnings per share of SEK 0.60 (1.09).
Pro forma
  • Sales, adjusted for discontinuing Covid business, increased by 18% in SEK, and 11% in local currencies.
  • EBITDA margin of 30.4% (34.4%).

Gothenburg, April 22, 2022
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.